These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
60 related articles for article (PubMed ID: 8423043)
1. Depression of drug-metabolizing activity in the human liver by interferon-beta. Okuno H; Takasu M; Kano H; Seki T; Shiozaki Y; Inoue K Hepatology; 1993 Jan; 17(1):65-9. PubMed ID: 8423043 [TBL] [Abstract][Full Text] [Related]
2. Depression of drug metabolizing activity in the human liver by interferon-alpha. Okuno H; Kitao Y; Takasu M; Kano H; Kunieda K; Seki T; Shiozaki Y; Sameshima Y Eur J Clin Pharmacol; 1990; 39(4):365-7. PubMed ID: 2076719 [TBL] [Abstract][Full Text] [Related]
3. Phase II clinical trial of combined natural interferon-beta plus recombinant interferon-gamma treatment of chronic hepatitis B. Musch E; Högemann B; Gerritzen A; Fischer HP; Wiese M; Kruis W; Malek M; Gugler R; Schmidt G; Huchzermeyer H; Gerlach U; Dengler HJ; Sauerbruch T Hepatogastroenterology; 1998; 45(24):2282-94. PubMed ID: 9951911 [TBL] [Abstract][Full Text] [Related]
4. [Effect of pegylated interferon beta-1a therapy on the liver fibrosis in chronic hepatitis C: a semi-quantitative analysis]. Rao HY; Li J; Zhang LF; Chen HY; Zhu LM; Wei L; Sun Y; Wang H Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(2):96-100. PubMed ID: 18353212 [TBL] [Abstract][Full Text] [Related]
5. NTP technical report on the toxicity studies of Dibutyl Phthalate (CAS No. 84-74-2) Administered in Feed to F344/N Rats and B6C3F1 Mice. Marsman D Toxic Rep Ser; 1995 Apr; 30():1-G5. PubMed ID: 12209194 [TBL] [Abstract][Full Text] [Related]
6. Modulation of effect of dietary salt on prehepatic first-pass metabolism: effects of beta-blockade and intravenous salt loading. Fromm MF; Darbar D; Dell'Orto S; Roden DM J Pharmacol Exp Ther; 1999 Jul; 290(1):253-8. PubMed ID: 10381784 [TBL] [Abstract][Full Text] [Related]
7. Effect of lamivudine on morphology and function of mitochondria in patients with chronic hepatitis B. Honkoop P; de Man RA; Scholte HR; Zondervan PE; Van Den Berg JW; Rademakers LH; Schalm SW Hepatology; 1997 Jul; 26(1):211-5. PubMed ID: 9214472 [TBL] [Abstract][Full Text] [Related]
8. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies). National Toxicology Program Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289 [TBL] [Abstract][Full Text] [Related]
9. [O-methyl 14C]naproxen O-demethylase activity in human liver microsomes: evidence for the involvement of cytochrome P4501A2 and P4502C9/10. Rodrigues AD; Kukulka MJ; Roberts EM; Ouellet D; Rodgers TR Drug Metab Dispos; 1996 Jan; 24(1):126-36. PubMed ID: 8825200 [TBL] [Abstract][Full Text] [Related]
10. Liver fibrosis and hepatic stellate cells improvement of chronic hepatitis C patients by interferon-beta-1a with or without sustained viral response. Rao HY; Wei L; Li J; Zhang LF; Chen HY; Zhu LM; Liu F; Sun Y; Wang H Hepatogastroenterology; 2009; 56(90):328-34. PubMed ID: 19579592 [TBL] [Abstract][Full Text] [Related]
11. [Effect of diclofop on the activity of some drug-metabolizing enzymes in the liver of male Wistar rats]. Palut D; Kostka G; Wiadrowska B; Bańkowski R Rocz Panstw Zakl Hig; 2002; 53(1):1-9. PubMed ID: 12053478 [TBL] [Abstract][Full Text] [Related]
12. Twice-a-day versus once-a-day interferon-beta therapy in chronic hepatitis C. Kaito M; Yasui-Kawamura N; Iwasa M; Kobayashi Y; Nakagawa N; Fujita N; Ikoma J; Gabazza EC; Watanabe S; Adachi Y Hepatogastroenterology; 2003; 50(51):775-8. PubMed ID: 12828083 [TBL] [Abstract][Full Text] [Related]
13. Age- and gender-related variations in the activities of drug-metabolizing and antioxidant enzymes in the white-footed mouse (Peromyscus leucopus). Guo Z; Wang M; Tian G; Burger J; Gochfeld M; Yang CS Growth Dev Aging; 1993; 57(2):85-100. PubMed ID: 8495997 [TBL] [Abstract][Full Text] [Related]
14. A pilot study of combination therapy with initial high-dose interferon and amantadine hydrochloride for patients with chronic hepatitis C with the genotype 1b virus. Uyama H; Enomoto H; Kishima Y; Yamamoto M; Yoshida K; Okuda Y; Hirotani T; Kuroda T; Ito H; Matsuda M; Terabayashi M; Noguchi S; Kawase I; Nakamura H Hepatogastroenterology; 2003; 50(54):2112-6. PubMed ID: 14696476 [TBL] [Abstract][Full Text] [Related]
15. Additive therapeutic effects of the liver extract preparation mixture adelavin-9 on interferon-beta treatment for chronic hepatitis C. Ebinuma H; Saito H; Tada S; Masuda T; Kamiya T; Nishida J; Yoshioka M; Ishii H; Hepatogastroenterology; 2004; 51(58):1109-14. PubMed ID: 15239256 [TBL] [Abstract][Full Text] [Related]
16. Comparison of interferon and lamivudine treatment in Japanese patients with HBeAg positive chronic hepatitis B. Arase Y; Ikeda K; Suzuki F; Suzuki Y; Kobayashi M; Akuta N; Hosaka T; Sezaki H; Yatsuji H; Kawamura Y; Kobayashi M; Kumada H J Med Virol; 2007 Sep; 79(9):1286-92. PubMed ID: 17607775 [TBL] [Abstract][Full Text] [Related]
17. Possible mechanism of induction of benign prostatic hyperplasia by estradiol and dihydrotestosterone in dogs. Winter ML; Liehr JG Toxicol Appl Pharmacol; 1996 Feb; 136(2):211-9. PubMed ID: 8619228 [TBL] [Abstract][Full Text] [Related]
19. Liver dysfunction markedly decreases the inhibition of cytochrome P450 1A2-mediated theophylline metabolism by fluvoxamine. Orlando R; Padrini R; Perazzi M; De Martin S; Piccoli P; Palatini P Clin Pharmacol Ther; 2006 May; 79(5):489-99. PubMed ID: 16678550 [TBL] [Abstract][Full Text] [Related]
20. Interferon treatment for patients with chronic hepatitis C infected with high viral load of genotype 2 virus. Nakamura H; Ogawa H; Kuroda T; Yamamoto M; Enomoto H; Kishima Y; Yoshida K; Ito H; Matsuda M; Noguchi S Hepatogastroenterology; 2002; 49(47):1373-6. PubMed ID: 12239945 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]